Aortic Cross-Clamping: Pathophysiology and Renal Protection Strategies

A Teaching Session for Anesthesia Residents

"Before we begin, I want you to approach this topic the way a vascular anesthesiologist thinks - not as a list of facts, but as a cascade of physiological dominoes. Once the clamp goes on, everything changes. Your job is to anticipate and blunt each domino."

PART 1: LEVELS OF CROSS-CLAMPING - WHY IT MATTERS

• Miller's Anesthesia, 10e, p. 7943

PART 2: PATHOPHYSIOLOGY OF AORTIC CROSS-CLAMPING

A. Cardiovascular - The Proximal Pressure Hammer

• Sudden increase in impedance to aortic flow
• Acute rise in LV systolic wall tension
• For supraceliac clamping: MAP increases by 54%, PCWP rises 38%, ejection fraction falls 38%
• For proximal descending thoracic clamping: CVP rises 56%, mean PA pressure rises 43%, PCWP rises 90%, cardiac index falls 29%
• For infrarenal clamping: changes are minimal; no wall motion abnormalities

• Splanchnic arterial flow drops sharply
• Intraluminal pressure in the highly compliant splanchnic veins falls
• These veins passively recoil and dump blood volume proximally
• Catecholamine surge (epinephrine + norepinephrine both rise sharply) causes active venoconstriction of the splanchnic bed, further squeezing blood centrally
• Net result: abrupt rise in ventricular preload on top of the afterload increase - a double hit on the left ventricle

• Supraceliac clamping causes LV end-systolic and end-diastolic areas to increase by 69% and 28% respectively
• Wall motion abnormalities indicative of ischemia develop in 11/12 patients even when systemic pressures are pharmacologically normalized (Roizen et al., JVSC 1984)
• This underscores that normalizing the pressure does NOT necessarily normalize myocardial function
• Miller's Anesthesia, 10e, pp. 7943-7945

B. Metabolic Changes During Cross-Clamping

• Miller's Anesthesia, 10e (Box 52.1), p. 7945

C. Unclamping - The Reperfusion Storm

1. Reactive hyperemia - reperfusion of ischemic beds causes profound vasodilation
2. Systemic vascular resistance can fall by up to 80%
3. Release of accumulated lactate, CO₂, adenosine, prostaglandins, and inflammatory mediators causes myocardial depression
4. Relative central hypovolemia - blood pools in the now-reperfused distal vascular beds
5. Cardiac output falls, hypotension can be profound
6. Ischemia-reperfusion injury releases reactive oxygen species (ROS), causing additional organ damage
7. LV pressure falls sharply

• Barash Clinical Anesthesia, 9e, pp. 3431-3432

PART 3: RENAL PATHOPHYSIOLOGY DURING CROSS-CLAMPING

Why does the kidney suffer even with infrarenal clamping?

• With infrarenal occlusion, renal blood flow decreases by nearly 50% from baseline
• Renal vascular resistance increases significantly
• The mechanism involves: renin-angiotensin activation (plasma renin activity rises during cross-clamping), neurohormonal activation, release of endothelin, myoglobin, and prostaglandins
• Blood flow is not just reduced but redistributed - flow preferentially goes to cortical and juxtamedullary layers, starving the metabolically active but poorly oxygenated outer medulla
• With suprarenal occlusion, renal blood flow decreases by up to 80%
• The incidence of acute renal failure is ~5% after infrarenal clamping and rises to ~13% after suprarenal clamping

Mechanism of Renal Injury:

1. Ischemic ATN - the dominant mechanism; accounts for nearly all renal dysfunction/failure after aortic reconstruction
2. Ischemia-reperfusion injury - ROS generation, endothelial cell activation, neutrophil infiltration on clamp release
3. Atheroemboli - cholesterol crystals from disrupted aortic plaques showering the renal microvasculature
4. Volume depletion - perioperative hypovolemia from blood loss, third spacing
5. Surgical trauma to renal arteries
6. Neurohormonal activation - angiotensin II, catecholamines, endothelin cause renal vasoconstriction
7. Postoperative hypotension propagates and worsens established renal injury

Strongest predictor of postoperative renal failure:

• Miller's Anesthesia, 10e, pp. 7956-7957
• Barash Clinical Anesthesia, 9e, p. 3431

PART 4: OPTIONS FOR RENAL PROTECTION - THE 5 Categories

Category 1: MINIMIZE ISCHEMIA TIME

• Shortest possible cross-clamp time is the single most effective intervention
• Segmental sequential clamping for thoracoabdominal repairs reduces cumulative ischemia to each vascular territory
• Efficient pre-clamp preparation (sutures ready, grafts on field)

Category 2: HEMODYNAMIC OPTIMIZATION - The Foundation

• Maintain adequate intravascular volume - avoid hypovolemia before AND after clamp application
• Maintain cardiac output - the kidney cannot be perfused by an empty pump
• Avoid prolonged hypotension - MAP targets should be maintained
• Maintain hematocrit - optimize oxygen delivery
• BUT: avoid excessive volume, which causes pulmonary edema, especially in patients with impaired myocardial reserve

• Miller's Anesthesia, 10e, p. 7914 | Barash, 9e, p. 3431

Category 3: PHARMACOLOGIC STRATEGIES (controversial but commonly used)

3a. Mannitol

• Dose: 12.5-25 g / 70 kg IV before cross-clamping
• Mechanisms:
  • Osmotic diuresis - maintains tubular flow, reduces cast formation
  • Reduces renal cortical blood flow reduction and endothelial cell swelling
  • Free radical scavenger - attenuates ischemia-reperfusion injury
  • Reduces renin secretion
  • Increases renal prostaglandin synthesis
• Status: Widely used ("ubiquitous in clinical practice") - Miller's description
• Not definitively proven in RCTs but mechanistically sound and low risk when volume is watched

3b. Low-dose Dopamine (1-3 mcg/kg/min)

• Acts on DA-1 and DA-2 receptors: renal and splanchnic vasodilation
• Increases renal blood flow and urine output intraoperatively
• BUT: dopamine does NOT clearly provide renal protection during ischemia
• Risks: positive chronotropy/inotropy may cause tachycardia and increase myocardial O₂ consumption - dangerous in patients with limited coronary reserve
• Can cause hypovolemia through diuresis, masking underperfusion
• Current status: controversial, without proof of efficacy - Morgan & Mikhail, 7e

3c. Fenoldopam Mesylate

• Selective dopamine-1 agonist - preferentially dilates renal and splanchnic vascular beds
• Avoids the adrenergic (tachycardia/inotropic) side effects of dopamine
• Has shown promise as a renoprotective agent
• However, its role in prevention of renal dysfunction after aortic surgery is not yet established
• May be preferred over dopamine when renal vasodilation is desired without the cardiac effects

3d. Loop Diuretics (furosemide)

• Mechanism: promote tubular flow, reduce O₂ demand in ascending loop of Henle (major site of ATN)
• Less effective than mannitol in experimental models
• Prophylactic use has not been shown to improve outcome in clinical studies
• Risk: can cause hypovolemia and worsen renal hypoperfusion if volume not replaced
• Current status: sometimes used, but evidence does not support routine use

3e. N-Acetylcysteine (NAC)

• Antioxidant; reduces ROS-mediated ischemia-reperfusion injury
• Evidence base is weak for surgical settings; extrapolated from contrast nephropathy data
• Commonly used in some centers without strong RCT evidence

3f. Statins

• Statin use is associated with preserved renal function after aortic surgery requiring suprarenal cross-clamping (observational data)
• Pleiotropic anti-inflammatory and antioxidant effects
• Perioperative continuation of statin therapy is recommended regardless

3g. Remote Ischemic Preconditioning (RIPC)

• Brief cycles of ischemia-reperfusion applied to a limb before major aortic surgery
• Reduces incidence of renal impairment after open aortic surgery (Miller's 10e)
• Mechanism: release of humoral and neural protective factors that prime organ resistance to ischemia
• Practical: inflate BP cuff to 200 mmHg on arm for 5 minutes x 4 cycles before surgery
• Low cost, no drug interactions, safe

Category 4: DISTAL AORTIC PERFUSION TECHNIQUES

• Passive shunts (Gott shunt, Sundt shunt): heparin-bonded tubing from proximal to distal aorta; no pump needed but cannot control flow
• Active distal aortic perfusion (partial bypass): left heart bypass (left atrium to descending aorta) or fem-fem bypass with centrifugal or roller pump - allows precise control of distal perfusion pressure
• Selective renal artery perfusion: cold (4°C) crystalloid perfusate directly into renal arteries via cannulas; combines perfusion with regional hypothermia
• These techniques are widely used to preserve renal and spinal cord function during TAAA repair
• Adequate bypass flow and distal arterial blood pressure are essential

Clinical pearl: Retrograde distal aortic perfusion is standard at most high-volume TAAA centers. It dramatically reduces renal and spinal cord ischemia compared to the "clamp-and-sew" technique.

• Miller's Anesthesia, 10e, p. 8002-8003

Category 5: HYPOTHERMIA

• Systemic hypothermia: reduces O₂ demand of all organs; every 1°C reduction in temperature reduces metabolic rate by ~7%
• Deep Hypothermic Circulatory Arrest (DHCA): used by some centers for extent III and IV TAAAs; virtually eliminates ischemic injury but introduces its own risks (coagulopathy, neurologic complications)
• Regional renal hypothermia:
  • Ice slush topical cooling around the kidneys
  • Cold (4°C) crystalloid perfusion directly into renal arteries
  • Most effective when combined with selective perfusion
• Regional hypothermia protects by reducing renal O₂ requirements during the ischemic period
• Miller's Anesthesia, 10e, p. 8002

PART 5: INTEGRATED MANAGEMENT SUMMARY

PRE-CLAMP:
- Optimize hydration (avoid hypovolemia)
- Mannitol 12.5-25 g/70 kg IV
- Fenoldopam infusion (if indicated)
- RIPC (if planned)
- Continue statins perioperatively
- TEE in situ for LV wall motion monitoring

DURING CLAMP:
- Afterload reduction: SNP or NTG for high-level clamps
- Preload management: volume loading (moderate, not excessive)
- Distal aortic perfusion (for thoracoabdominal)
- Selective renal perfusion with cold crystalloid
- Monitor UO (not reliable alone but trends matter)
- Minimize clamp time

UNCLAMPING:
- Reduce vasodilators before clamp release
- Volume load in anticipation of redistribution
- Gradual, controlled clamp release (communicate with surgeon)
- Vasopressors ready (phenylephrine, norepinephrine, epinephrine/CaCl2)
- Decrease anesthetic depth if needed

POST-CLAMP:
- Watch for metabolic acidosis
- Correct hypovolemia, maintain MAP
- Monitor for delayed AKI
- Avoid nephrotoxins (NSAIDs, contrast, aminoglycosides)

PART 6: VIVA QUESTIONS (with model answers)

A: Preoperative renal dysfunction. The degree of pre-existing renal insufficiency is the most powerful independent predictor. This is why preoperative creatinine, eGFR, and proteinuria must be documented.

A: Several mechanisms operate even with an infrarenal clamp: (1) activation of the renin-angiotensin system raises angiotensin II, causing renal vasoconstriction; (2) sympathetic activation releases catecholamines; (3) release of endothelin, a potent renal vasoconstrictor; (4) altered prostaglandin balance. Net result: RBF decreases by ~50% even below the clamp. With suprarenal occlusion, RBF falls by up to 80%.

A: I expect:

• MAP rises ~54% above the clamp - severe proximal hypertension
• PCWP rises ~38% - splanchnic blood shifts proximally, increasing preload
• CVP rises - same mechanism
• Cardiac index may fall - despite increased filling pressures, the LV cannot cope with the abrupt afterload increase
• Ejection fraction falls ~38% - ventricular dilation
• LV end-systolic and end-diastolic areas increase - sign of failing ventricle
• Wall motion abnormalities - regional ischemia in 11/12 patients in Roizen's study, even when pressures are pharmacologically normalized
• Mixed venous O₂ saturation rises - ischemic tissue distal to clamp cannot extract O₂

A: The splanchnic circulation contains about 25% of total blood volume. Two thirds of this (>800 mL) can be autotransfused within seconds via passive recoil of compliant splanchnic veins when arterial inflow is cut off. Additionally, catecholamine surge causes active venoconstriction of the highly adrenergically sensitive splanchnic veins, squeezing additional blood centrally. This autotransfusion into the proximal, non-compliant venous system causes the dramatic rise in CVP and PCWP.

A: (1) Osmotic diuresis - maintains tubular flow and prevents tubular sludging and cast formation; (2) reduces endothelial cell swelling in renal cortical blood vessels; (3) free radical scavenging - attenuates ischemia-reperfusion injury; (4) reduces renin secretion - blunts vasoconstriction; (5) increases renal prostaglandin synthesis - vasodilatory effect. It is given 12.5-25 g/70 kg before cross-clamping.

A: Despite its theoretical mechanism (DA-1 receptor-mediated renal vasodilation and natriuresis), clinical evidence does not show that dopamine clearly prevents renal ischemia. Risks include tachycardia and increased myocardial O₂ consumption from beta-1 effects - especially dangerous in patients with limited coronary reserve. It can also cause diuresis that masks underperfusion. Fenoldopam mesylate (a selective DA-1 agonist) achieves renal vasodilation without the adrenergic side effects and is preferred when pharmacologic renal vasodilation is desired. However, it too lacks definitive evidence of efficacy in aortic surgery.

A: RIPC involves applying brief, repeated cycles of ischemia-reperfusion to a distant organ (typically the limb - BP cuff inflated to 200 mmHg for 5 minutes, released, repeated x 4 cycles) before the index ischemic event. The kidneys (and other organs) become preconditioned to withstand ischemia better. The mechanisms involve release of humoral protective factors (adenosine, bradykinin, nitric oxide) and activation of neural protective pathways that reduce apoptosis, oxidative stress, and inflammation in target organs. Evidence from open aortic surgery shows a reduced incidence of renal impairment with RIPC.

A: During TAAA repair requiring suprarenal clamping, direct cannulation of the renal arteries allows perfusion with cold (4°C) crystalloid or blood. This achieves two things simultaneously: (1) regional hypothermia reduces renal O₂ consumption; (2) continued substrate delivery. This is superior to simple cross-clamping alone. Combined with distal aortic perfusion via partial left heart bypass, it significantly reduces the incidence of postoperative renal failure in TAAA repair.

A: "Declamp hypotension" - a profound fall in SVR (up to 80%), release of accumulated anaerobic metabolites (lactate, CO₂, adenosine, prostaglandins), reactive hyperemia in the reperfused distal beds causing massive redistribution of circulating volume away from the central circulation. Cardiac output falls due to reduced preload and myocardial depression from metabolic mediators. Management: (1) moderate volume loading during the clamp period; (2) anticipate - reduce vasodilators and anesthetic depth before release; (3) communicate with the surgeon for a controlled, gradual release; (4) have vasopressors (phenylephrine, norepinephrine) and inotropes (epinephrine, calcium chloride) ready; (5) NaHCO₃ if severe metabolic acidosis.

A: Multi-pronged approach:

1. Identify and document baseline renal function (creatinine, GFR) - the strongest predictor of outcome
2. Optimize preoperative hydration - avoid all nephrotoxins (contrast, NSAIDs, aminoglycosides) in the preoperative period
3. Mannitol 12.5-25 g/70 kg IV before clamp application
4. Maintain cardiac output and MAP - this is the most important modifiable intraoperative factor
5. Consider fenoldopam infusion if there is pre-existing renal disease
6. RIPC if institutional protocol supports it
7. Discuss with surgeon about selective renal artery perfusion with cold crystalloid
8. Minimize cross-clamp time - clear communication, efficient preparation
9. Avoid hypotension throughout - especially at unclamping
10. Continue statins perioperatively
11. Postoperatively: avoid nephrotoxins, maintain volume, watch urine output and creatinine trend

A: Infrarenal clamping causes only modest cardiovascular changes - minimal changes in MAP, PCWP, or wall motion because the clamped vascular bed is small and significant collateral circulation usually exists. Supraceliac clamping causes the most profound changes: MAP increases 54%, PCWP increases 38%, EF falls 38%, LV areas increase dramatically, and nearly all patients develop new wall motion abnormalities. This is because the entire splanchnic and visceral circulation (plus kidneys) is excluded, with massive blood volume redistribution, catecholamine surge, and acute LV pressure-volume overload.

Sources

• Miller's Anesthesia, 10th Edition (2024) - Chapters 52 (Vascular Surgery)
• Barash Clinical Anesthesia, 9th Edition - Chapter 40 (Vascular Surgery)
• Morgan & Mikhail's Clinical Anesthesiology, 7th Edition - Chapter 31 (Renal Physiology & Anesthesia)
• Gelman S. The pathophysiology of aortic cross-clamping and unclamping. Anesthesiology. 1995;82(4):1026-1060. (Classic reference)
• Roizen MF et al. Monitoring with 2D TEE: comparison of myocardial function during aortic occlusion. J Vasc Surg. 1984;1:300-305.

Miller's Anesthesia: 10th Edition (2024) vs. 9th Edition (2019)

A Comparative Analysis for MD Final Exam Preparation

"Understanding why a textbook changes is as important as knowing what changed. Every addition to Miller's reflects what the specialty considers important enough to codify. For your MD finals, examiners want you to know not just the content, but the evolution of thinking."

PART 1: OVERVIEW - AT A GLANCE

PART 2: DIRECT CHAPTER-BY-CHAPTER COMPARISON

SECTION I - INTRODUCTION

• Global health equity was elevated to a standalone chapter because the Lancet Commission on Global Surgery (2015) and COVID-19 exposed massive disparities in access to safe anesthesia - over 5 billion people lack access to safe, affordable surgical/anesthetic care.
• Informatics was expanded because EHRs, AI decision support, and big data analytics have become part of daily anesthetic practice.

SECTION II - ANESTHETIC PHYSIOLOGY

1. COVID-19 demonstrated that anesthesiologists must understand immunopathology (cytokine storm, immune-mediated lung injury)
2. Growing evidence that volatile anesthetics are immunomodulatory - they suppress NK cell function, alter T-cell activity
3. Cancer surgery anesthesia debate (TIVA vs. volatile: immune preservation)
4. Perioperative immunosuppression in transplant/oncology patients is now a subspecialty
5. Biologics and checkpoint inhibitor drugs (immunotherapy) have perioperative anesthetic implications

• Innate vs. adaptive immunity review
• How volatile anesthetics (sevoflurane, desflurane) suppress immune function vs. propofol (TIVA) which is relatively immune-sparing
• Neuroinflammation and POCD (links to Ch 78 on neurocognitive disorders)
• Anesthetic management in immunocompromised patients
• COVID-19-era protocols for high-risk airway management

SECTION III - ANESTHETIC MANAGEMENT (Preoperative/Intraoperative)

• ASE/ACEP/SCCM endorsement of POCUS as a core competency
• POCUS-guided fluid management (IVC collapsibility, lung B-lines) now standard of care
• Ultrasound-guided airway (identifying CTM, trachea) for emergency airway
• Point-of-care echo for hemodynamic assessment in the OR and ICU

SECTION IV - ADULT SUBSPECIALTY MANAGEMENT (Volume 2)

SECTION - EXTREME ENVIRONMENTS (Split into 2 chapters in 10th ed)

SECTION V - PEDIATRIC ANESTHESIA

SECTION VI - POSTOPERATIVE CARE

SECTION VII - CRITICAL CARE MEDICINE

SECTION VIII - ANCILLARY RESPONSIBILITIES (BIGGEST CHANGES)

PART 3: THE TWO COMPLETELY NEW CHAPTERS - DEEP DIVE

NEW CHAPTER 1: The Immune System - Implications for Anesthetic Management

• Volatile anesthetics (halogenated agents) suppress NK cell cytotoxicity, reduce T-cell proliferation, and decrease cytokine release
• Propofol (TIVA) is relatively immune-sparing and has been associated with better cancer recurrence outcomes in some retrospective studies (though no definitive RCT)
• Perioperative immunosuppression peaks at 24-72 hours post-surgery (surgical stress + anesthetic effects)
• Neuroinflammation from surgery + anesthesia contributes to POCD/PND
• Drug interactions: checkpoint inhibitors (pembrolizumab, nivolumab) + anesthesia; biologics (infliximab, adalimumab); immunosuppressants in transplant

NEW CHAPTER 2: Emergency Preparedness in Health Care

• Hospital incident command systems
• Surge capacity planning for the OR/ICU
• Mass casualty triage (START, SALT triage)
• PPE protocols and airway management in highly infectious patients
• Drug and equipment shortage management
• Disaster anesthesia - ketamine as the backbone agent

PART 4: THEMATIC CHANGES AND WHY THEY MATTER

Theme 1: COVID-19 Integration

• Airway management (aerosol-generating procedures, use of video laryngoscopy, modified RSI)
• Respiratory physiology (COVID-19 ARDS, "atypical ARDS" - Type L vs. Type H phenotypes)
• Critical care (prone positioning protocols, HFNC vs. NIV, dexamethasone)
• Occupational safety (N95 vs. surgical masks; fit testing)
• Obstetrics (COVID-19 in pregnancy, safe neuraxial timing)
• Informatics (telemedicine preoperative assessment)

Theme 2: POCUS Revolution

• Echocardiography chapter explicitly retitled to include POCUS
• Peripheral nerve block chapter explicitly retitled to include ultrasound guidance
• New content: lung ultrasound, gastric ultrasound (POCUS for aspiration risk assessment), airway ultrasound
• Reflects ASE and ACEP guidelines mandating POCUS competency

Theme 3: Sustainability and Environmental Responsibility

• Desflurane has been removed from many institutions globally due to its 2,540x global warming potential vs. CO₂
• Sevoflurane (130x GWP) is being scrutinized; TIVA and nitrous oxide-free techniques promoted
• The 10th edition explicitly addresses the carbon footprint of anesthesia gases
• Halogenated agent recapture devices discussed
• This reflects the British Journal of Anaesthesia/Lancet Planet Health calls for "Green Anesthesia"

Theme 4: Perioperative Neurocognitive Disorders (PND) - Nomenclature Update

• Preoperative Neurocognitive Disorder (existing before surgery)
• Delayed Neurocognitive Recovery (within 30 days - old "POCD")
• Postoperative Neurocognitive Disorder (>30 days)
• Perioperative Stroke This is a common viva topic.

Theme 5: Structural Reorganization

PART 5: VIVA QUESTIONS FOR MD FINAL EXAMS

A: (1) The Immune System: Implications for Anesthetic Management - added because COVID-19 and oncology anesthesia (TIVA vs. volatiles debate) demonstrated that anesthesiologists need formal understanding of immunomodulation by anesthetic agents, management of immunocompromised patients, and perioperative neuroinflammation; (2) Emergency Preparedness in Health Care - added following lessons learned from COVID-19 pandemic, which exposed critical gaps in hospital surge capacity, PPE protocols, and mass casualty preparedness among anesthesia providers.

A: The 9th edition mentioned ultrasound within individual chapters without a dedicated framework. The 10th edition systematically elevated POCUS to a core competency by: (1) renaming the echocardiography chapter to explicitly include POCUS ("Perioperative Echocardiography and Point-of-Care Ultrasound"); (2) renaming the peripheral nerve block chapter to include "Ultrasound Guidance for Regional Anesthesia"; (3) adding new content on lung ultrasound, gastric ultrasound for aspiration risk, and airway ultrasound; (4) expanding pediatric POCUS for nerve blocks. This reflects ASE, ACEP, and SCCM guidelines declaring POCUS a mandatory competency.

A: The 10th edition includes new content on sustainability and green anesthesia - absent from the 9th edition. Desflurane has a global warming potential 2,540 times that of CO₂ and has been withdrawn from many institutions in the UK and Europe. Sevoflurane has a GWP of ~130. The 10th edition discusses: discontinuation of desflurane, promotion of TIVA and low-flow anesthesia, halogenated gas recapture technology, and the anesthesiologist's responsibility toward environmental stewardship. This reflects global climate action in medicine.

A: Over 5 billion people lack access to safe, affordable surgical and anesthetic care. The Lancet Commission on Global Surgery found that 143 million additional surgical procedures are needed annually in LMICs. Anesthesia-related mortality in LMICs is 100-1000x higher than in high-income countries, often due to lack of pulse oximetry, trained providers, and safe drugs. The 10th edition argues that global health equity is an ethical imperative for the specialty - not a peripheral concern. This chapter was not present in the 9th edition and signals the specialty's evolution.

A: The 9th edition used POCD (Postoperative Cognitive Dysfunction) throughout. The 10th edition adopts the 2018 International Study of Postoperative Cognitive Decline (ISPOCD) consensus terminology: (1) Preoperative Neurocognitive Disorder - pre-existing cognitive impairment; (2) Delayed Neurocognitive Recovery - cognitive decline within 30 days post-surgery (the old "POCD"); (3) Postoperative Neurocognitive Disorder - decline persisting beyond 30 days; (4) Perioperative Stroke - new focal neurological deficits. The chapter also links neuroinflammation from surgery and anesthesia to the immune chapter, integrating these topics.

A: Dr. Johnson-Akeju (MGH/Harvard) replaced Dr. Jeanine Wiener-Kronish. His addition signals a deliberate thematic shift: his research focuses on mechanisms of anesthetic-induced unconsciousness and neuroinflammation. More broadly, his inclusion reflects the specialty's commitment to diversity, equity, and inclusion in leadership - aligning with the new Global Health Equity chapter and the overall 10th edition theme of making anesthesia more globally representative and inclusive.

A: The new Immune System chapter directly addresses this. Volatile anesthetic agents suppress NK cell cytotoxicity and T-cell function perioperatively. Propofol-based TIVA is relatively immune-sparing and may preserve anti-tumor immune surveillance. Retrospective data and some RCTs suggest TIVA may be associated with reduced cancer recurrence in certain cancers (breast, colon). However, the 10th edition is appropriately cautious - it states that prospective RCT data are insufficient to mandate TIVA for cancer surgery. The MYRIAD trial (ongoing) and similar studies are cited. This is now an examinable topic.

A: The 9th edition had a single comprehensive chapter on all extreme environments (Ch 74). The 10th edition split this into two separate chapters: Ch 70: Clinical Care in Extreme Environments - Physiology at High Altitude and in Space and Ch 71: High Pressure, Immersion, Drowning, Hypo- and Hyperthermia. The split reflects expanding content - spaceflight medicine has grown with commercial spaceflight, and underwater/drowning management has new evidence. Separating them improves clarity and depth.

A: Four key changes: (1) The pediatric critical care chapter was renamed to explicitly include "Neonatal Critical Care" (Ch 75), reflecting expansion of neonatal ECMO, therapeutic hypothermia for HIE, and neonatal pharmacology; (2) The pediatric anesthesia chapter was substantially expanded with updated content on the FDA neurotoxicity warning for children under 3 years (SMART Act); (3) POCUS-guided nerve blocks in children were added; (4) Congenital cardiac anesthesia was updated with 3D echo, hybrid procedures, and HLHS staged repair. The overall message: neonatal and pediatric subspecialty anesthesia has grown in complexity and deserves more granular coverage.

A: Pembrolizumab and similar checkpoint inhibitors cause immune activation (not suppression) - they block inhibitory pathways, leading to potential immune-related adverse events (irAEs). Perioperative risks include: (1) anesthetic-agent interaction - volatile agents may blunt the anti-tumor immune response that checkpoint inhibitors are trying to maintain; TIVA (propofol) is therefore theoretically preferable in cancer patients on immunotherapy; (2) Steroid pre-treatment for irAEs affects the HPA axis - stress-dose steroids may be required; (3) Risk of pneumonitis (immune-mediated lung injury) - assess respiratory reserve; (4) Myocarditis (rare but fatal irAE) - preoperative ECG and troponin recommended; (5) Timing of surgery relative to immunotherapy cycle should be discussed with oncology team.

A: Both editions dedicate a full chapter to adult airway management. Key updates in the 10th: (1) Videolaryngoscopy (VL) is now positioned as the primary choice for anticipated or unexpected difficult airway in many scenarios - in the 9th, direct laryngoscopy was still primary with VL as backup; (2) The ASA Difficult Airway Algorithm was updated (2022 revision included); (3) COVID-19 section added: modified RSI, video laryngoscopy preference for aerosol-generating procedures, use of barrier devices; (4) Ultrasound of the airway (identifying CTM, tracheal rings) added; (5) High-flow nasal oxygen (THRIVE - Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) added for apnoeic oxygenation.

A: The 9th edition covered desflurane as a standard clinical choice with its known properties (low blood-gas solubility, rapid emergence, airway irritability). The 10th edition, while retaining pharmacological content, adds a sustainability perspective: desflurane has a GWP of 2,540x CO₂ over 100 years and 3,714x over 20 years. Its use has been voluntarily discontinued in many European institutions (UK, France, Germany). The 10th edition explicitly discusses this environmental concern and promotes low-flow techniques, TIVA, and desflurane recapture as alternatives. In the UK, desflurane was effectively banned from NHS use in 2021. This makes it an important viva topic.

SUMMARY TABLE - KEY CHANGES AT A GLANCE

• Miller's Anesthesia, 10th Edition (Gropper et al., Elsevier, 2024) - ISBN 9780323935920
• Miller's Anesthesia, 9th Edition (Gropper et al., Elsevier, 2019) - ISBN 9780323596046
• Elsevier Publisher's official chapter listing (shop.elsevier.com)
• Full-text peer review: Cumpstey AF, Pandit JJ, Kelleher EM. British Journal of Anaesthesia. September 2025
• Reviewer: Insler JE (Yale). Elsevier Health. 2024